LRP5 and retinal disorder: We next evaluated the efficacy of a NDP mimetic FZD4:LRP5 antibody agonist to reduce the formation of pathologic retinal neovascularization (NV) in the oxygen‐induced retinopathy (OIR) model, which exhibit pathological features reminiscent of retinopathy of prematurity (ROP) and other human retinopathies such as diabetic retinopathy.